Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Diffusion Pharmaceuticals Inc DFFN

Healthcare Biotechnology
Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapies that may enhance the body’s ability to deliver oxygen to the areas. Its advanced product candidate, Trans Sodium Crocetinate (TSC), is developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine... see more

Recent & Breaking News (NDAQ:DFFN)

Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma

GlobeNewswire August 15, 2023

IMPORTANT ALERT: Halper Sadeh LLC Investigates CFMS, DFFN, ARNC, GRNA

PR Newswire June 23, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FOCS, RADI, BGRY, DFFN

PR Newswire May 22, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HSKA, LSI, EXR, DFFN

PR Newswire April 3, 2023

DIFFUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Diffusion Pharmaceuticals Inc. - DFFN

Business Wire March 31, 2023

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Diffusion Pharmaceuticals Inc. Merger

Newsfile March 30, 2023

Moore Kuehn Encourages DFFN, KMF, CSTI, and BGRY Investors to Contact Law Firm

PR Newswire March 30, 2023

DFFN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Diffusion Pharmaceuticals Inc. Is Fair to Shareholders

Business Wire March 30, 2023

EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases

GlobeNewswire March 30, 2023

Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities

GlobeNewswire December 16, 2022

Diffusion Pharmaceuticals Sends Letter to Stockholders Highlighting Strength of Board Leadership and Positive Progress in Strategic Review, Cautioning Stockholders Regarding LifeSci's History of Stockholder Value Destruction and Self-Dealing

GlobeNewswire December 5, 2022

Diffusion Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire November 14, 2022

Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process

GlobeNewswire November 14, 2022

Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC

GlobeNewswire October 25, 2022

Diffusion Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire August 11, 2022

Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation

GlobeNewswire July 26, 2022

Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial

GlobeNewswire June 23, 2022

Diffusion Pharmaceuticals Announces Appointment of Raven Jaeger, M.S., as Chief Regulatory Officer

GlobeNewswire May 18, 2022

Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

GlobeNewswire May 17, 2022

Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire May 12, 2022